Decreased platelet APP isoform ratios in autosomal dominant Alzheimer’s disease: Baseline data from a DIAN cohort subset

Current Alzheimer Research

Volumn 12, Issue 2, 2015, Pages 157-164

  Chatterjee, Pratishtha ^a,b,c   Gupta, Veer B ^b,c   Fagan, Anne M ^f   Jasielec, Mateusz S ^f,g   Xiong, Chengjie ^f,g   Sohrabi, Hamid R ^a,b,c   Dhaliwal, Satvinder ^d   Taddei, Kevin ^b,c   Bourgeat, Pierrick ^e   Brown, Belinda M ^a,b,c   Benzinger, Tammie ^f,h   Bateman, Randall J ^f   Morris, John C ^f   Martins, Ralph N ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c McCusker Alzheimer's Research foundation   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer s disease; Amyloid precursor protein; Biomarkers; Neuropsychological tests; Pittsburgh compound B; Platelets

Indexed keywords

AMYLOID PRECURSOR PROTEIN; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; APOLIPOPROTEIN E4; APP PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ADULT; ALZHEIMER DISEASE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CAUDATE NUCLEUS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PRECUNEUS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THROMBOCYTE; WESTERN BLOTTING; BLOOD; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; GENETICS; ISOMERISM; LONGITUDINAL STUDY; MENTAL HEALTH; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGY; WESTERN AUSTRALIA;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; BLOTTING, WESTERN; CAUDATE NUCLEUS; FEMALE; HETEROZYGOTE; HUMANS; ISOMERISM; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; PARIETAL LOBE; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES; WESTERN AUSTRALIA;

EID: 84989227764     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150204125732     Document Type: Article

References (41)

1. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, et al. Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell 57(1): 115-26 (1989).
2. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, et al. The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem 265(26): 15977-83 (1990).
3. Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, et al. [alpha]-Secretase ADAM10 as well as alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med 8(2): 67-74 (2002).
4. Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease. J Neurol Sci 240(1-2): 53-8 (2006).
5. Colciaghi F, Marcello E, Borroni B, Zimmermann M, Caltagirone C, Cattabeni F, et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62(3): 498-501 (2004).
6. Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CM. Platelet phospholipase A(2) activity in Alzheimer’s disease and mild cognitive impairment. J Neural Transm 111(5): 591-601 (2004).
7. Zubenko GS, Cohen BM, Reynolds CF, 3rd, Boller F, Malinakova I, Keefe N. Platelet membrane fluidity in Alzheimer’s disease and major depression. Am J Psychiatry 144(7): 860-8 (1987).
8. Matsushima H, Shimohama S, Fujimoto S, Takenawa T, Kimura J. Reduction of platelet phospholipase C activity in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 9(4): 213-7 (1995).
9. Neumann K, Farias G, Slachevsky A, Perez P, Maccioni RB. Human platelets tau: a potential peripheral marker for Alzheimer’s disease. J Alzheimers Dis 25(1): 103-9 (2011).
10. Ortiz GG, Pacheco-Moises F, El Hafidi M, Jimenez-Delgado A, Macias-Islas MA, Rosales Corral SA, et al. Detection of membrane fluidity in submitochondrial particles of platelets and erythrocyte membranes from Mexican patients with Alzheimer disease by intramolecular excimer formation of 1,3 dipyrenylpropane. Dis Markers 24(3): 151-6 (2008).
11. Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, et al. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54(2): 139-44 (1997).
12. Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 55(9): 1195-200 (1998).
13. Sanchez-Gonzalez VJ, Ortiz GG, Gallegos-Arreola P, Macias-Islas MA, Arias-Merino ED, Loera-Castaneda V, et al. Altered betaamyloid precursor protein isoforms in Mexican Alzheimer’s Disease patients. Dis Markers 22(3): 119-25 (2006).
14. Zainaghi IA, Talib LL, Diniz BS, Gattaz WF, Forlenza OV. Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer’s disease. J Neural Transm 119(7): 815-9 (2012).
15. Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, et al. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology 57(12): 2243-8 (2001).
16. Pastorino L, Colciaghi F, Marcon G, Borroni B, Cottini E, Cattabeni F, et al. Presenilin 2 mutation does not influence expression and concentration of APP forms in human platelets. Mol Med 6(10): 816-24 (2000).
17. Baskin F, Rosenberg RN, Iyer L, Schellenberg GD, Hynan L, Nee LE. Platelet APP isoform ratios in asymptomatic young adults expressing an AD-related presenilin-1 mutation. J Neurol Sci 183(1): 85-8 (2001).
18. Tomita S, Kirino Y, Suzuki T. Cleavage of Alzheimer’s amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. J Biol Chem 273(11): 6277-84 (1998).
19. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367(9): 795-804 (2012).
20. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer’s Disease Cooperative Study experience. Neurology 48(6): 1508-10 (1997).
21. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr 21(4): 672-87 (2009).
22. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am 15(4): 869-77, 11-12 (2005).
23. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27(23): 6174-84 (2007).
24. Benzinger TLS, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci USA 110(47): E4502-9 (2013).
25. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer’s disease. Brain 131(Pt 7): 1845-53 (2008).
26. Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 54(10): 1907-9 (2000).
27. Borroni B, Colciaghi F, Archetti S, Marcello E, Caimi L, Di Luca M, et al. Predicting cognitive decline in Alzheimer disease. Role of platelet amyloid precursor protein. Alzheimer Dis Assoc Disord 18(1): 32-4 (2004).
28. Srisawat C, Junnu S, Peerapittayamongkol C, Futrakul A, Soi- Ampornkul R, Senanarong V, et al. The platelet amyloid precursor protein ratio as a diagnostic marker for Alzheimer’s disease in Thai patients. J Clin Neurosci 20(5): 644-8. (2013).
29. Liu HC, Wang HC, Ko SY, Wang PN, Chi CW, Hong CJ, et al. Correlation between platelet amyloid precursor protein isoform ratio and cognition in Alzheimer’s disease. J Alzheimers Dis 11(1): 77-84 (2007).
30. Di Luca M, Pastorino L, Cattabeni F, Zanardi R, Scarone S, Racagni G, et al. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol 53(11): 1162-6 (1996).
31. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2(8): 864-70 (1996).
32. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 213(1): 96-103 (1995).
33. Vignini A, Sartini D, Morganti S, Nanetti L, Luzzi S, Provinciali L, et al. Platelet amyloid precursor protein isoform expression in Alzheimer’s disease: evidence for peripheral marker. Int J Immunopathol Pharmacol 24(2): 529-34 (2011).
34. Bush AI, Tanzi RE. Alzheimer disease-related abnormalities of amyloid beta precursor protein isoforms in the platelet: the brain’s delegate in the periphery? Arch Neurol 55(9): 1179-80 (1998).
35. Bermejo-Bescos P, Martin-Aragon S, Jimenez-Aliaga K, Benedi J, Felici E, Gil P, et al. Processing of the Platelet Amyloid Precursor Protein in the Mild Cognitive Impairment (MCI). Neurochem Res 38(7):1415-23 (2013).
36. Mullan M, Houlden H, Crawford F, Kennedy A, Rogues P, Rossor M. Age of onset in familial early onset Alzheimer’s disease correlates with genetic aetiology. Am J Med Genet 48(3): 129-30 (1993).
37. Catricala S, Torti M, Ricevuti G. Alzheimer disease and platelets: how’s that relevant. Immun Ageing 9(1): 20 (2012).
38. Cattabeni F, Colciaghi F, Di Luca M. Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 28(5): 763-70 (2004).
39. Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A. Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Exp Gerontol 45(1): 53-6 (2010).
40. Valla J, Schneider L, Niedzielko T, Coon KD, Caselli R, Sabbagh MN, et al. Impaired platelet mitochondrial activity in Alzheimer’s disease and mild cognitive impairment. Mitochondrion 6(6): 323-30 (2006).
41. Holly SP, Chen X, Parise LV. Abundance- and Activity-Based Proteomics in Platelet Biology. Curr Proteomics 8(3): 216-28 (2011).